Cover Image
市場調查報告書

雷諾氏症:開發平台分析

Raynauds Disease - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200484
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
雷諾氏症:開發平台分析 Raynauds Disease - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 53 Pages
簡介

所謂雷諾氏現象(RP),是指氣溫大幅上升、下降和遇到情緒壓力時,手指和腳尖變色的現象。皮膚的變色,是由於血管的異常收縮使末梢組織的血液供應量減少而產生。由於長時間的供氧不足導致手指變藍。如果血管再次擴張,便在該處產生「潮紅」現象,手指變紅。這樣的皮膚連續變色是雷諾氏症的特徵。雷諾氏症的治療包含了可保持血管擴張狀態的醫藥品等。用溫水浸手,及寒冷的時候保持手腳溫暖狀態等,往往相當有效。

本報告提供全球各國治療雷諾氏症所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查結果。

簡介

  • 分析範圍

治療藥的開發

  • 雷諾氏症開發中產品:概要
  • 雷諾氏症開發中產品:比較分析

雷諾氏症概要

治療藥的開發

  • 雷諾氏症開發中產品:概要
  • 雷諾氏症開發中產品:比較分析

各企業開發中的雷諾氏症治療藥

大學/研究機關研究中的雷諾氏症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

雷諾氏症治療藥:開發中的產品一覽(各企業)

雷諾氏症治療藥:研究中的產品一覽(大學/研究機關別)

雷諾氏症開發治療藥的企業

  • Allergan Plc
  • Apricus Biosciences, Inc.
  • Bayer AG
  • Covis Pharmaceuticals, Inc.
  • Human Stem Cells Institute

雷諾氏症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • acetylcysteine
  • alprostadil
  • ELS-140
  • Neovasculgen
  • nitroglycerin
  • onabotulinumtoxin A
  • riociguat

雷諾氏症治療藥:最新開發平台趨勢

雷諾氏症治療藥:暫停中的計劃

雷諾氏症治療藥:開發中止的產品

雷諾氏症相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8379IDB

Summary

Global Markets Direct's, 'Raynauds Disease - Pipeline Review, H2 2016', provides an overview of the Raynauds Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Raynauds Disease
  • The report reviews pipeline therapeutics for Raynauds Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Raynauds Disease therapeutics and enlists all their major and minor projects
  • The report assesses Raynauds Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Raynauds Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Raynauds Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Raynauds Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Raynauds Disease Overview
  • Therapeutics Development
    • Pipeline Products for Raynauds Disease - Overview
  • Raynauds Disease - Therapeutics under Development by Companies
  • Raynauds Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Raynauds Disease - Products under Development by Companies
  • Raynauds Disease - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Apricus Biosciences, Inc.
    • Covis Pharmaceuticals, Inc.
    • Human Stem Cells Institute
  • Raynauds Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acetylcysteine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alprostadil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ELS-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neovasculgen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitroglycerin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Raynauds Disease - Dormant Projects
  • Raynauds Disease - Discontinued Products
  • Raynauds Disease - Product Development Milestones
    • Featured News & Press Releases
      • Mar 08, 2016: Apricus Biosciences to Present at the 28th Annual ROTH Conference
      • Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference, Provide Update on Vitaros
      • Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference
      • Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May
      • Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa
      • Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon
      • Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa
      • Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum
      • May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon
      • Dec 13, 2012: MediQuest Therapeutics To Conduct Meetings At J.P. Morgan Conference Regarding Phase III Topical Formulation Vascana
      • May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon
      • Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa
      • Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma
      • Jan 10, 2006: MediQuest Therapeutics Receives Special Protocol Assessment From The U.S. FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Raynauds Disease, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Raynauds Disease - Pipeline by Allergan Plc, H2 2016
  • Raynauds Disease - Pipeline by Apricus Biosciences, Inc., H2 2016
  • Raynauds Disease - Pipeline by Covis Pharmaceuticals, Inc., H2 2016
  • Raynauds Disease - Pipeline by Human Stem Cells Institute, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Raynauds Disease - Dormant Projects, H2 2016
  • Raynauds Disease - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Raynauds Disease, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top